5 completed, 1 unknown. 2 Not applicable, 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow MenACWY vaccine: new trials by email Literature Review of MenACWY vaccine trials Research Report on MenACWY vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women Iron supplementation, MenACWY vaccine, COVID-19 vaccine - Iron Deficiency Anemia | Not applicable | Unknown | Swiss Federal Institute of Technology | 180 | 2023-11-01 | 2024-01-24 |
| Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women Oral iron supplementation (pre-treatment), COVID-19 vaccine, MenACWY vaccine - Iron Deficiency Anemia | Not applicable | Completed | Nicole Stoffel | 180 | 2023-07-01 | 2025-12-26 |
| A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. Trumenba Vaccine, MenACWY Vaccine - Gonorrhea, Chlamydia | Completed | Pfizer | 1307378 | 2023-04-24 | 2025-04-17 | |
| A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo - Infections, Meningococcal | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1440 | 2021-06-14 | 2025-05-31 |
| Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine MenABCWY vaccine, Placebo, MenACWY vaccine - Meningitis, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 1250 | 2021-01-25 | 2024-07-03 |
| Investigating a Vaccine Against COVID-19 ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost - Coronavirus | Phase 2 / Phase 3 | Completed | University of Oxford | 10811 | 2020-05-28 | 2025-09-03 |
Anemia, Iron-Deficiency (2) · Meningococcal Infections (2) · Anemia (1) · COVID-19 (1) · Chlamydia Infections (1) · Coronavirus Infections (1) · Gonorrhea (1) · Iron Deficiencies (1) · Meningitis, Meningococcal (1)
GlaxoSmithKline (2) · Nicole Stoffel (1) · Pfizer (1) · Swiss Federal Institute of Technology (1) · University of Oxford (1)
United States (3) · Australia (2) · Kenya (2) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Finland (1) · Poland (1) · Sweden (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Andrew Pollard, Prof (1) · Simon Karanja, PhD (1)
PMID 33220855, PMID 33306989, PMID 33335323, PMID 33617777, PMID 33798499, PMID 34153264, PMID 34480858, PMID 35192543, PMID 39722560
2019 (1)